If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
66.50    0.50 (0.76%)
Bid:
66.00
Ask:
67.00
Spread: 1.00 (1.515%)
Market Cap: £80.67m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

Directorate Change

20 Sep 2018 07:01

RNS Number : 3208B
Venture Life Group PLC
20 September 2018
 

20 September 2018

Venture Life Group plc

("Venture Life" or the "Company")

 

Directorate Change

 

Venture Life (AIM: VLG), the international consumer self-care company focused on developing, manufacturing and commercialising products for the self-care market, announces the appointment of Carl Dempsey as a Non-Executive Director to replace John Sylvester who has stepped down from the Board to focus on his other executive commitments. These Board changes take place with immediate effect.

 

Until recently, Carl was Worldwide Vice President Global Customer Management at Johnson & Johnson ("J&J") where he was responsible for global sales of US$3.6 billion across 22 countries. During his 29 year career at J&J, Carl had particular responsibility for developing the Health and Wellness Partnership strategy. He also led the successful integration of Pfizer Consumer Healthcare across Europe, Africa and the Middle East which included the Listerine mouthwash brand.

Dr Lynn Drummond, Non-Executive Chair of Venture Life, commented: "We are delighted to welcome Carl to the Board. His wide variety of international roles and experience gained in his long career at J&J will no doubt prove to be a valuable asset to the rest of the Board as we seek to continue growing the business both organically and via acquisitions.

 

"On behalf of the Board, I would like to thank John for his contribution to the Company. He has been with Venture Life since our IPO in 2014 and we have appreciated his guidance during this time and we wish him all the best for the future."

 

Further information on Carl Dempsey

 

Carl Douglas Dempsey (aged 56) has in the last five years been a director of Johnson & Johnson Consumer Services (EAME) Limited and is currently a director of Big Blue Bear Limited.

 

There is no further information on Carl Dempsey required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.

 

For further information please contact:

Venture Life Group PLC

+44 (0) 1344 742870

Jerry Randall, Chief Executive Officer

Adrian Crockett, Chief Financial Officer

Northland Capital Partners Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 3861 6625

Matthew Johnson / Edward Hutton (Corporate Finance)

Vadim Alexandre (Corporate Broking)

Cenkos Securities plc (Joint Broker)

+44 (0) 207 397 8900

Mark Connelly (Corporate Finance)

Russell Kerr / Michael Johnson (Sales)

Walbrook PR

venturelife@walbrookpr.com or + 44 (0) 20 7933 8780

Anna Dunphy / Paul McManus

+44 (0) 7876 741 001 / +44 (0) 7980 541 893

 

About Venture Life (www.venture-life.com) 

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in both the UK and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and proctology and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK these are supplied direct by the company, outside of the UK they are supplied by the Group's international distribution partners. 

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOABLGDCXDBBGIC
Date   Source Headline
12th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20257:00 amRNSTransaction in Own Shares
10th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20257:00 amRNSSale of Non-Core Products
8th Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20254:30 pmRNSTotal Voting Rights
1st Dec 20257:00 amRNSTransaction in Own Shares
28th Nov 20257:00 amRNSTransaction in Own Shares
25th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20257:00 amRNSTransaction in Own Shares
3rd Oct 20254:40 pmRNSDirector/PDMR Shareholding
30th Sep 20257:01 amRNSShare Buyback Programme
30th Sep 20257:00 amRNSInterim Results
29th Sep 202512:19 pmRNSInvestor Presentation via Investor Meet Company
24th Sep 20252:38 pmRNSChange of Accounting Reference Date
8th Sep 20257:00 amRNSDirectorate Change
19th Aug 20252:04 pmRNSHolding(s) in Company
5th Aug 20253:43 pmRNSResult of General Meeting
25th Jul 20257:05 amRNSGrant of Share Options
25th Jul 20257:00 amRNSCompletion of Divestment & Trading Update
7th Jul 20254:21 pmRNSDirector/PDMR Shareholding
3rd Jul 20257:00 amRNSDirector Dealings
2nd Jul 20257:00 amRNSNotice of General Meeting & Investor Presentation
1st Jul 20254:08 pmRNSHolding(s) in Company
30th Jun 20253:15 pmRNSResult of AGM
30th Jun 20253:13 pmRNSFinal Results for year ended 31 December 2024
5th Jun 20252:19 pmRNSNotice of Annual General Meeting
19th May 20257:01 amRNSDirector Dealings
19th May 20257:00 amRNSBoard Update
12th May 20258:49 amRNSReplacement: Cash sale of CDMO operations
12th May 20257:00 amRNSCash sale of CDMO operations
28th Apr 202510:50 amRNSHolding(s) in Company
8th Apr 20254:53 pmRNSHolding(s) in Company
20th Feb 20251:14 pmRNSHolding(s) in Company
18th Feb 202510:02 amRNSHolding(s) in Company
4th Feb 20257:01 amRNSBoard Changes
4th Feb 20257:00 amRNSTrading Statement
21st Jan 20258:15 amRNSExercise of Share Options & Total Voting Rights
20th Jan 202511:49 amRNSHolding(s) in Company
19th Dec 202411:48 amRNSHolding(s) in Company
4th Nov 20243:44 pmRNSHolding(s) in Company
30th Oct 202412:01 pmRNSDirector/PDMR Shareholding
30th Oct 202410:58 amRNSDirector/PDMR Shareholding
30th Oct 20247:00 amRNSAcquisition of Health & Her Limited
1st Oct 202412:47 pmRNSHolding(s) in Company
30th Sep 20247:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.